You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

KRAS-Mutated CRC

Showing 1 - 25 of 1,967
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, NSCLC Trial (ELI-002 7P)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +14 more
  • ELI-002 7P
  • (no location specified)
Feb 3, 2023

NSCLC (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma Advanced Solid Tumors Trial in Irving, San Antonio,

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma Advanced Solid Tumors
  • Assigned interventions
  • Irving, Texas
  • +2 more
Nov 7, 2023

KRAS P.G12C, Pancreatic Cancer Trial in Beijing (JAB-21822)

Not yet recruiting
  • KRAS P.G12C
  • Pancreatic Cancer
  • Beijing, Beijing, China
  • +1 more
Aug 18, 2023

Advanced Solid Tumor, NSCLCs Trial in Houston (Adagrasib, Olaparib)

Not yet recruiting
  • Advanced Solid Tumor
  • Non-small Cell Lung Cancers
  • Houston, Texas
    M D Anderson Cancer Center
Nov 15, 2023

Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation Trial (Onvansertib, FOLFIRI, Bevacizumab)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • +2 more
  • (no location specified)
Oct 24, 2023

Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer Trial in United States (BMF-219)

Recruiting
  • Non Small Cell Lung Cancer
  • +16 more
  • Goodyear, Arizona
  • +10 more
Jan 24, 2023

Solid Tumor, KRAS Mutation-Related Tumors Trial in Washington (NEROFE, Doxorubicin)

Recruiting
  • Solid Tumor
  • KRAS Mutation-Related Tumors
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Jan 23, 2023

Cholangiocarcinoma Trial (GNS561 + Trametinib)

Not yet recruiting
  • Cholangiocarcinoma
  • GNS561 + Trametinib
  • (no location specified)
May 22, 2023

Minimal Residual Disease, KRAS G12D, KRAS G12R Trial in United States (ELI-002 2P)

Recruiting
  • Minimal Residual Disease
  • +11 more
  • ELI-002 2P
  • Duarte, California
  • +10 more
Jan 18, 2023

KRAS P.G12C, Non Small Cell Lung Cancer Trial in France (Sotorasib 120Mg Tab)

Recruiting
  • KRAS P.G12C
  • Non Small Cell Lung Cancer
  • Sotorasib 120Mg Tab
  • Lyon, France
  • +3 more
Dec 16, 2022

RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC

Recruiting
  • Nsclc
  • KRAS P.G12C
    • Paris, France
    • +2 more
    Aug 9, 2022

    Colorectal Cancer Trial in Hangzhou (IBI351)

    Not yet recruiting
    • Colorectal Cancer
    • Hangzhou, Zhejiang, China
      The Second Affiliated Hospital of Zhejiang University School of
    Aug 9, 2022

    Gastrointestinal Cancer Trial in New York, Providence (Cobimetinib, Hydroxychloroquine, Atezolizumab)

    Active, not recruiting
    • Gastrointestinal Cancer
    • New York, New York
    • +1 more
    Nov 29, 2022

    Pancreatic Ductal Adenocarcinoma Trial in New York (VSV-GP154, ATP150, ATP152)

    Recruiting
    • Pancreatic Ductal Adenocarcinoma
    • New York, New York
      NYU Langone Health
    May 4, 2023

    NSCLC Trial in Philadelphia (Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days))

    Recruiting
    • Non-Small Cell Lung Cancer
    • Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
    • Philadelphia, Pennsylvania
      Fox Chase Cancer Center
    Jul 29, 2022

    NSCLC Trial in Baltimore (Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides
    • Baltimore, Maryland
      Johns Hopkins University
    Jun 16, 2022

    Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression = 1% and an STK11

    Recruiting
    • Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
    • Montpellier, France
    • +7 more
    Dec 19, 2022

    Colo-rectal Cancer Trial in Manchester (therascreen® KRAS RGQ PCR Kit)

    Recruiting
    • Colo-rectal Cancer
    • therascreen® KRAS RGQ PCR Kit
    • Manchester, United Kingdom
      QIAGEN Gaithersburg, Inc
    Apr 20, 2022

    NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors Trial in Belgium, Netherlands, United Kingdom (LNP3794)

    Active, not recruiting
    • NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
    • Brussels, Belgium
    • +3 more
    Dec 24, 2021

    KRAS Gene Mutation, Metastatic Malignant Tumor in the Brain, Recurrent Non-Small Cell Lung Carcinoma Trial in Palo Alto

    Active, not recruiting
    • KRAS Gene Mutation
    • +3 more
    • Palo Alto, California
      Stanford University School of Medicine
    Feb 9, 2022

    NSCLC Trial in Shanghai, Hangzhou (D-1553, Other)

    Not yet recruiting
    • NSCLC
    • Shanghai, Shanghai, China
    • +1 more
    Aug 11, 2022

    Advanced Solid Tumor (Phase 1), Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous) Trial in United States (IMM-1-104)

    Recruiting
    • Advanced Solid Tumor (Phase 1)
    • +4 more
    • Duarte, California
    • +4 more
    Feb 2, 2023

    Pancreatic Cancer, Colorectal Cancer, NSCLC Trial in Amsterdam (RMC-4630, LY3214996)

    Not yet recruiting
    • Pancreatic Cancer
    • +3 more
    • (no location specified)
    Mar 9, 2022

    Solid Tumor, ARID1A Gene Mutation Trial in Greenville (Tazemetostat)

    Suspended
    • Solid Tumor
    • ARID1A Gene Mutation
    • Greenville, South Carolina
      Prisma Health Cancer Institute
    Jan 10, 2023

    Solid Tumors, KRAS Mutation; SOS1 Trial in Germany, Netherlands, United States (BI 1701963, Trametinib)

    Active, not recruiting
    • Solid Tumors, KRAS Mutation; SOS1
    • Boston, Massachusetts
    • +7 more
    Aug 22, 2022